An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft tissue sarcoma, according to a recent study published in The Lancet Oncology. “These findings support the combination as a potential treatment option for patients with advanced leiomyosarcoma and provide a strong rationale for further study aimed at improving outcomes in this difficult-to-treat cancer,” said Seth Pollack, MD, the Steven T. Rosen, MD, Professor of Cancer Biology and a co-author of the study.
This article was originally published on MedicalXpress.com
